MedTrace Logo

Estimation of (suPAR) in Chronic Periodontitis With Post-radiotherapy on HNCs Patients

NCT06529588 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-07-31

No results posted yet for this study

Summary

This study aims to improve a soluble urokinase plasminogen activator receptor suPAR is a reliable biomarker of chronic periodontitis and may be replaced in patients with head and neck cancer post-radiotherapy (HNC post-RT).

Conditions

Interventions

RADIATION

Radiation

HNCs patients who received radiotherapy was exposure (5700-7000 Gys) for fractions number (32-35) after 6 months

Sponsors & Collaborators

  • Al-Maarif University College

    lead OTHER

Principal Investigators

  • Ahmed A. Al-Kubaisi, PhD · Al-Maarif University College

Eligibility

Min Age
28 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-01-09
Completion
2023-10-23

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06529588 on ClinicalTrials.gov